Compare United States Oil ETF (USO) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
United States Oil ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? United States Oil ETF trades at $130.26, while Vertex Pharmaceuticals Incorporated trades at $478.12 (market cap $121.95B). Which is the better fit depends on your goals.
| USO | VRTX | |
|---|---|---|
52-Week High | $152.96 | $529.59 |
52-Week Low | $66.17 | $366.54 |
Market Cap | — | $121.95B |
Sector | — | Health |
Enterprise Value | — | $116.69B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
USO trades at $125.51, up 1.25% with a bullish technical signal driven by moving averages. Recent news highlights Middle East supply disruptions as a key catalyst, with oil prices testing resistance levels. The stock shows strong momentum but overbought RSI readings suggest caution near-term.
Outlook remains positive given geopolitical tensions supporting oil prices, though elevated RSI indicates potential pullback risk. Key support sits at $124, with resistance at $127. Investors face volatility from supply shocks and inflation concerns, requiring careful position management.
Vertex Pharmaceuticals (VRTX) trades at $482.00, down 0.75% on the day, with mixed technical signals showing a bullish overall trend but bearish moving averages. The company maintains strong fundamentals with $12.0B revenue (2025), 35.51% net margin, and recent earnings beats. Vertex's $10B acquisition of Crinetics Pharmaceuticals adds significant growth potential in endocrinology treatments.
The outlook remains positive with 85.7% analyst buy ratings and $538 consensus target offering 11.6% upside. Key risks include integration challenges from the Crinetics acquisition and competitive pressures in biopharmaceutical markets. Strong cash flow generation and profitability support continued growth despite recent volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About United States Oil ETF
This ETF invests primarily in futures contracts for light, sweet crude oil, other types of crude oil, diesel-heating oil, gasoline, natural gas, and other petroleum-based fuels.
Read more on USO →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
